Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Eukaryotic Gene Expression
IF: 2.156 5-Year IF: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Print: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2019026184
pages 243-249

Association between ABCB1 G2677T/A Polymorphism and Breast Cancer Risk: A Meta-Analysis

Hongchao Liu
The New Area People's Hospital of Luoyang
Zhihao Wei
Department of Pathology, The New Area People's Hospital of Luoyang, The Teaching Hospital of Henan University of Science and Technology, Luoyang 471023, Henan Province, People's Republic of China
Kangke Shi
Department of Pathology, The New Area People's Hospital of Luoyang, The Teaching Hospital of Henan University of Science and Technology, Luoyang 471023, Henan Province, People's Republic of China
Yu Zhang
Department of Pathology, The New Area People's Hospital of Luoyang, The Teaching Hospital of Henan University of Science and Technology, Luoyang 471023, Henan Province, People's Republic of China

ABSTRACT

Several studies have investigated the relationship between ABCB1 G2677T/A polymorphism and breast cancer susceptibility; however, the published results remain controversial. Thus, we conducted a meta-analysis to synthetically evaluate the association of this polymorphism with breast cancer risk. A computerized literature search was systematically carried out in PubMed, EMBASE, ScienceDirect, China National Knowledge Infrastructure and Wanfang Databases to identify the published case-control studies investigating the relationship between ABCB1 G2677T/A polymorphism and breast cancer risk. The strength of association was assessed using odds ratios (ORs) with 95% confidence intervals (CIs). In total, six studies, including 4,791 cases and 7,042 controls, were included. The results of our quantitative synthesis suggest that there is no significant association between ABCB1 G2677T/A polymorphism and breast cancer risk in overall comparisons under four genetic models (heterozygote: OR = 1.01, 95% CI = 0.92–1.09, P = 0.90; homozygote: OR = 1.01, 95% CI = 0.65–1.55, P = 0.97; recessive model: OR = 1.06, 95% CI = 0.75–1.50, P = 0.76; and dominant model: OR = 0.98, 95% CI = 0.77–1.24, P = 0.85). Similarly, no significant association was observed in the stratification analyses by ethnicity and control source. In conclusion, this meta-analysis suggests that ABCB1 G2677T/A polymorphism is not associated with genetic susceptibility to breast cancer.

REFERENCES

  1. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63:88-105.

  2. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics. 2008;9:1879-902.

  3. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16:446.

  4. Palomba G, Loi A, Porcu E, Cossu A, Zara I, Budroni M, Dei M, Lai S, Mulas A, Olmeo N, Ionta MT, Atzori F, Cuccuru G, Pitzalis M, Zoledziewska M, Olla N, Lovicu M, Pisano M, Abecasis GR, Uda M, Tanda F, Michailidou K, Easton DF, Chanock SJ, Hoover RN, Hunter DJ, Schlessinger D, Sanna S, Crisponi L, Palmier G, Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. BMC Cancer. 2015;15:383.

  5. Haryono SJ, Datasena IG, Santosa WB, Mulyarahardja R, Sari K. A pilot genome-wide association study of breast cancer susceptibility loci in Indonesia. Asian Pac J Cancer Prev. 2015;16:2231-5.

  6. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, Perkins BJ, Czene K, Eriksson M, Darabi H, Brand JS, Bojesen SE, Nordestgaard BG, Flyger H, Nielsen SF, Rahman N, Turnbull C; BOCS, Fletcher O, Peto J, Gibson L, dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Khan S, Aaltonen K, Ahsan H, Kibriya MG, Whittemore AS, John EM, Malone KE, Gammon MD, Santella RM, Ursin G, Makalic E, Schmidt DF, Casey G, Hunter DJ, Gapstur SM, Gaudet MM, Diver WR, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Berg CD, Chanock SJ, Figueroa J, Hoover RN, Lambrechts D, Neven P, Wildiers H, van Limbergen E, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, Couch FJ, Olson JE, Hallberg E, Vachon C, Waisfisz Q, et.all Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47:373.

  7. Schinkel AH. The physiological function of drug- transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161-70.

  8. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genom. 2011;21:152-61.

  9. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004;10:RA5-14.

  10. Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 2013;65:445-54.

  11. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and 19. clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.

  12. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein- -implications of metabolism ofneoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5:457-68.

  13. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006;79:325-38.

  14. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72:209-19.

  15. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-8.

  16. Rubis B, Holysz H, Barczak W, Gryczka R, Lacinski M, Jagielski P, Czernikiewicz A, Polrolniczak A, Wojewoda A, Perz K, Bialek P, Morze K, Kandula Z, Lisiak N, Mrozikiewicz PM, Grodecka-Gazdecka S, Rybczynska M. Study of ABCB1 polymorphism frequency in breast cancer patients from Poland. Pharmacol Rep. 2012;64:1560-66.

  17. Wu H, Kang H, Liu Y, Tong W, Liu D, Yang X, Lian M, Yao W, Zhao H, Huang D, Sha X, Wang E, Wei M. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol. 2012;138:1449-62.

  18. Abbas S, Beckmann L, Chang-Claude J, Hein R, Kropp S, Parthimos M, Dunnebier T, Hamann U, Brors B, Eils 26. R, Zapatka M, Brauch H, Justenhoven C, Flesch-Janys D, Bruning T, Pesch B, Spickenheuer A, Baisch C, Ko YD, Dahmen N, Abbas S, Brauch H, Chang-Claude J, Dunnebier T, Flesch-Janys D, Hamann U, Hein R, Justenhoven C, Salazar R. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. 2010;120:727-36.

  19. Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lenning PE, Berresen-Dale AL, Kristensen VN. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genom. 2007;17:127-36.

  20. Abuhaliema AM, Yousef AM, El-Madany NN, Bulatova NR, Awwad NM, Yousef MA, Al Majdalawi KZ. Influence of genotype and haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the incidence of breast cancer-a case-control study in Jordan. Asian Pac J Cancer Prev. 2016;17:261-66.

  21. Fawzy MS, Awad HA, Ahmad HS, Kamel LM, Tom MM. Multi-drug resistance 1 genetic polymorphisms gene expression and prediction of chemotherapy response in breast cancer Egyptian patients. Egypt J Biochem Mol Biol. 2014;32:75-98.

  22. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-28.

  23. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, Yates CR. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol. 2006;46:373-79.

  24. Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006;107:2850-57.

  25. Zheng Q, Wu H, Yu Q, Kim DH, Lipton JH, Angelini S, Soverini S, Vivona D, Takahashi N, Cao J. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenom J. 2015;15:127-34.

  26. Wang Z, Wang T, Bian J. Association between MDR1 C3435T polymorphism and risk of breast cancer. Gene. 2013;532:94-99.


Articles with similar content:

Association between the Epithelial Cadherin − 160C/A Polymorphism and Colorectal Cancer Risk: Evidence from a Meta-Analysis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Lei Zhang, Jiansong Jiang, Jianfeng Chen, Ningjie Sun, Xiansheng Chen, Gang Hu, Haiming Wu
TCF7L2 rs12255372 (G > T) Polymorphism Contributes to Breast Carcinogenesis: Evidence from a Meta-Analysis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.23, 2013, issue 4
Qun Zhang, Zexing Wang, Weiwei Nie, Fengxia Chen, Bin Yang, Yanru Wang, Xiaoxiang Guan
Association between Methionine Synthase Reductase A66G Polymorphism and Male Infertility: A Meta-Analysis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 1
Fan Jin, Xiangli Wu, Lin Zhang, Weihai Xu
XRCC1 Arg194Trp and Arg280His Polymorphisms in Bladder Cancer Susceptibility: A Meta-Analysis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.23, 2013, issue 4
Guangjun Jiao, Qinghua Yin, Lian Li, Chuan Liu, Yajie Wang, Mei Wang
Association of ERCC1 and ERCC2 Gene Polymorphisms with Pancreatic Cancer Risk: A Meta-Analysis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.30, 2020, issue 3
Fuyi Xie, Yinyu Mu, Qi Sun, En Zhang